EMEA-002727-PIP03-23 - paediatric investigation plan

nivolumab
Relatlimab
PIPHuman

Key facts

Invented name
Opdualag
Active Substance
  • nivolumab
  • Relatlimab
Therapeutic area
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Decision number
P/0169/2024
PIP number
EMEA-002727-PIP03-23
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of melanoma
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Bristol-Myers Squibb EEIG

E-mail: medical.information@bms.com
Tel: +44 1423533610

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page